Where can researchers source third-party tested Cagrilintide?

Midwest Peptide supplies research-grade Cagrilintide with a Certificate of Analysis included for every batch, validated by HPLC purity and mass spectrometry identity testing.

Age Verification

You must be 21 years or older to access this website. All products are for research use only.

Are you 21 years of age or older?

By entering, you confirm that you are at least 21 years old and agree to our terms of service.

Free shipping on every orderFree shipping on every order

5% off with Zelle or Apple CashSave an extra 5% when you pay with Zelle or Apple Cash

Bulk pricing discounts up to 18%Bulk pricing discounts up to 18% off

Cagrilintide Weight Maintenance Research | Midwest Peptide

Where to Buy Cagrilintide for Research: Amylin Analog Sourcing GuidePrev|Cagrilintide Gastric Emptying Research: Postprandial Animal Model StudiesNext

Cagrilintide Weight Maintenance Research: Long-Term Rodent Literature

Cagrilintide · Published April 14, 2026 · Updated May 18, 2026 · 7 min read

Quick Answer

Cagrilintide weight maintenance research examines chronic body composition outcomes in rodent obesity models during long-term amylin receptor activation. Studies measure sustained body weight, fat mass distribution, lean tissue preservation, and metabolic biomarker dynamics over extended dosing periods. For research use only, not for human consumption.

Cagrilintide Weight Maintenance Research: Long-Term Rodent Literature

Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.

The Weight Maintenance Research Question
Long Term Rodent Data with Cagrilintide
Body Composition Preservation
Combination Research with Semaglutide
Comparison with Pramlintide Long Term Research
Metabolic Endpoint Stability
Research Design for Long Term Studies
Research Peptides Referenced
Related Research Reading
Related Research Articles
Explore Related Products
Frequently Asked Questions
Glossary

Cagrilintide weight maintenance research addresses the long term question of whether sustained body composition effects can be achieved with chronic administration of a long acting amylin analog. The cagrilintide research cluster covers the acute satiety and gastric emptying effects that drive initial body composition changes. This article extends the analysis into the chronic rodent research that examines weight maintenance over weeks to months of continued dosing.

Frequently Asked Questions

What is Cagrilintide in research contexts?

Cagrilintide is a long-acting synthetic amylin analog modified for extended half-life. It is studied in preclinical research models for its effects on satiety, gastric emptying, food intake, and body composition through amylin and calcitonin receptor signaling.

How is weight maintenance studied with Cagrilintide?

Long-term rodent obesity protocols measure body weight stability after initial weight loss, comparing Cagrilintide-treated animals against vehicle controls and pair-fed groups. Studies extend to 12 weeks or longer to capture sustained effects.

What does Cagrilintide research show about weight regain?

Cagrilintide-treated rodent obesity models show preserved weight loss with continued dosing and reduced rebound weight regain compared to controls upon dose cessation, suggesting durable changes in food intake and energy balance setpoints.

Is Cagrilintide approved for human use?

No. Cagrilintide is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.

Glossary

Key terms used in this article.

Amylin: A 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells, involved in postprandial glucose regulation and satiety.
Calcitonin Receptor: The class B GPCR that, when complexed with RAMP proteins, forms functional amylin receptors AMY1, AMY2, and AMY3.
RAMP: Receptor activity-modifying proteins (RAMP1, RAMP2, RAMP3) that combine with the calcitonin receptor to define amylin receptor subtypes.
Satiety: The sensation of fullness following food intake, regulated by gut peptides, central nervous system signaling, and hormonal cues.
CagriSema: A research combination of cagrilintide and semaglutide studied for amylin and GLP-1 pathway synergy.
Diet-Induced Obesity (DIO): A rodent model created by chronic high-fat or high-energy diet exposure to study obesity and metabolic disease.
Energy Balance: The relationship between energy intake and energy expenditure, the determinant of body weight changes over time.

More from the Blog

Continue exploring research insights and updates.

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Subcutaneous vs intranasal administration for CNS-targeted research peptides: how to choose between routes for DSIP, Selank, and Kisspeptin based on molecular size, brain access, pharmacokinetics, and the published literature.

May 5, 2026

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

FDA restricted compounded tirzepatide for human use when the shortage ended. The Research Use Only research peptide channel for tirzepatide (GLP-2 TZ) operates under entirely separate regulations.

May 5, 2026

For Research Use Only. Cagrilintide is intended strictly for in vitro and preclinical animal research. It is not approved for human use, is not a drug, and should never be administered to humans.

The Weight Maintenance Research Question

Initial body composition effects of metabolic interventions are generally easier to achieve than sustained effects. Most compounds that reduce food intake produce weight loss during the active dosing period, but the weight is often regained after discontinuation or plateaus at a level that is not maintained with continued dosing. Weight maintenance research examines whether an intervention can produce sustained body composition changes under chronic administration conditions, which is a more stringent test of the underlying biology.

The rodent research models for this question typically involve diet induced obesity models in which animals are maintained on a high fat diet to produce an obese phenotype, followed by intervention with the test compound over extended dosing periods. Body weight, body composition, and metabolic endpoints are monitored throughout the dosing period and often during a post treatment follow up to assess rebound. The integrated biology is documented in primary research archived at the Nature subject hub on obesity and in the Cell Press journal Cell Metabolism.

Long Term Rodent Data with Cagrilintide

Published rodent research on cagrilintide includes studies with dosing durations extending to several months in diet induced obese models. The data documents sustained body weight reduction throughout the dosing period, sustained reduction in fat mass with preservation of lean mass, and sustained improvements in metabolic endpoints including glucose regulation and lipid profile.

The sustained nature of the weight effect is mechanistically important. The gastric emptying deceleration and the central satiety effects continue throughout the dosing period because the long acting pharmacokinetic profile provides continuous receptor engagement. Partial tachyphylaxis has been reported in some long term studies, with the rate of weight loss slowing over time as the animals approach a new body weight set point, but the weight is generally maintained below baseline throughout the dosing period.

The ScienceDirect body weight regulation topic page archives primary research on the neurobiology of body weight set point regulation that provides useful context for interpreting the chronic cagrilintide findings.

Body Composition Preservation

The body composition changes under chronic cagrilintide administration show preferential reduction in fat mass with preservation of lean mass. This is the desired body composition outcome for most research applications because loss of lean mass would be undesirable in most contexts. The mechanism favoring fat mass reduction involves the metabolic shift toward fatty acid oxidation and the reduced food intake that together produce an energy deficit that is preferentially extracted from adipose stores.

Dual energy X ray absorptiometry and magnetic resonance imaging are the standard methods for body composition quantification in rodent research. Published cagrilintide studies using these methods document the fat mass preferential reduction consistently across the literature. The ratio of fat mass loss to lean mass loss is favorable and compares well with other metabolic interventions in matched models.

Combination Research with Semaglutide

Combined administration of cagrilintide plus semaglutide, discussed in the cagrisema research article in this cluster, has been studied in long term rodent research. The combination produces larger and more sustained body weight effects than either compound alone, which is consistent with the complementary mechanisms of action that each contributes.

Amylin receptor agonism through cagrilintide and GLP-1 receptor agonism through semaglutide engage different receptor systems that both support satiety and body composition effects. The additive or synergistic combination has been documented in multiple published studies, and the research on the combination continues to generate interest because it provides a mechanistic test case for combined peptide interventions in metabolic research.

The combination is supported by the parallel Midwest Peptide catalog offerings of Cagrilintide 5mg and GLP-1 SM 20mg, both as research grade products with third party certificates of analysis.

Comparison with Pramlintide Long Term Research

The cagrilintide versus pramlintide comparison article in this cluster addresses the general comparative analysis. For long term research specifically, the distinction between the short acting and long acting amylin analogs becomes particularly important. Pramlintide requires multiple daily doses to maintain receptor engagement, which is logistically demanding in long term rodent research. Cagrilintide requires dosing every three to seven days depending on the specific protocol, which is more practical and better matched to the kinetics of chronic studies.

The sustained receptor engagement provided by cagrilintide also produces different downstream adaptation patterns than the pulsatile engagement provided by pramlintide. The chronic data reflects the sustained engagement paradigm and may not directly translate to conclusions about pulsatile amylin signaling in physiology.

Metabolic Endpoint Stability

Beyond body weight, metabolic endpoints under chronic cagrilintide administration show stability throughout the dosing period. Fasting glucose is maintained at improved levels. Insulin sensitivity indices show sustained improvement. Lipid profile improvements are maintained. The integrated metabolic stability is consistent with the chronic body composition improvements and supports the interpretation that the intervention produces a sustained shift in the metabolic phenotype rather than only an acute effect.

The Wiley Online Library endocrinology collection and the Frontiers in Endocrinology open access journal archive primary research on long term metabolic intervention research that provides useful context.

Research Design for Long Term Studies

Long term cagrilintide research requires careful design to capture the full temporal profile of the response. Dosing schedules should reflect the pharmacokinetics of the compound, which supports dosing intervals of three to seven days depending on the specific protocol requirements. Body weight and composition should be measured at defined time points throughout the study, with the sampling frequency matched to the expected rate of change.

Food intake should be measured continuously or at frequent intervals because the food intake reduction is a core component of the body composition effect. Energy expenditure can be measured through indirect calorimetry during defined periods to characterize any energy expenditure contribution to the net body weight effect.

Post treatment follow up is important for assessing the durability of the effects after discontinuation. Rebound weight gain is common after discontinuation of any weight reducing intervention, and the magnitude and timing of the rebound is informative about the underlying biology.

Research Peptides Referenced

Cagrilintide 5mg, research grade long acting amylin analog, third party COA
GLP-1 SM 20mg, GLP-1 receptor agonist for combination research
GLP-2 TZ 30mg, dual incretin agonist (for comparison)
GLP-3 RT, triple incretin agonist (for comparison)

For complete sourcing information, see the cagrilintide sourcing guide in this cluster.

Within the cagrilintide cluster:

Related cluster pillars:

Not for human consumption. Research use only.

Explore more peer-reviewed research and laboratory guides from our science team:

All products are third-party tested with a Certificate of Analysis (COA) included. For research use only.

GLP-1 SM 20mg, 99%+ purity, COA included
Cagrilintide 10mg, 99%+ purity, COA included
GLP-2 TZ , 99%+ purity, COA included
GLP-3 RT, 99%+ purity, COA included

Browse All Research Peptides →

Age Verification

Cagrilintide Weight Maintenance Research: Long-Term Rodent Literature

Frequently Asked Questions

What is Cagrilintide in research contexts?

How is weight maintenance studied with Cagrilintide?

What does Cagrilintide research show about weight regain?

Is Cagrilintide approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

The Weight Maintenance Research Question

Long Term Rodent Data with Cagrilintide

Body Composition Preservation

Combination Research with Semaglutide

Comparison with Pramlintide Long Term Research

Metabolic Endpoint Stability

Research Design for Long Term Studies

Research Peptides Referenced

Ready to Start Your Research?

Where can researchers source third-party tested Cagrilintide?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?

Age Verification

Cagrilintide Weight Maintenance Research: Long-Term Rodent Literature

Frequently Asked Questions

What is Cagrilintide in research contexts?

How is weight maintenance studied with Cagrilintide?

What does Cagrilintide research show about weight regain?

Is Cagrilintide approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

The Weight Maintenance Research Question

Long Term Rodent Data with Cagrilintide

Body Composition Preservation

Combination Research with Semaglutide

Comparison with Pramlintide Long Term Research

Metabolic Endpoint Stability

Research Design for Long Term Studies

Research Peptides Referenced

Related Research Reading

Related Research Articles

Explore Related Products

Ready to Start Your Research?

Where can researchers source third-party tested Cagrilintide?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?